IMPACT Therapeutics (7630) investor relations material

Executive summary

• Revenue for the six months ended June 30, 2026, rose to RMB105.2 million, up 316.8% year-over-year, driven by strong senaparib sales and increased licensing income following NRDL inclusion and expanded market access in China.

• Net loss narrowed by 29.5% to RMB90.8 million, with adjusted net loss (Non-HKFRS) down to RMB20.9 million.

• Completed a successful IPO on the Hong Kong Stock Exchange in May 2026, raising HK$879 million in net proceeds.

• Entered an exclusive license agreement with Pharmanovia for senaparib in 66 countries, unlocking significant milestone and royalty potential.

• Advanced multiple clinical and preclinical pipeline assets, with key data presentations at major oncology conferences.

Financial highlights

• Sales of pharmaceutical products reached RMB70.4 million, up 877.8% year-over-year; licensing revenue was RMB34.8 million.

• Gross profit reached RMB95.5 million, with a gross margin of 90.8%, slightly down from 97.7% in the prior year.

• Loss for the period narrowed to RMB90.8 million from RMB128.7 million year-over-year.

• Adjusted net loss (Non-HKFRS) was RMB20.9 million, a significant improvement from RMB55.8 million.

• Cash and financial assets totaled RMB1,065.4 million as of June 30, 2026, up from RMB258.5 million at year-end 2025.

Outlook and guidance

• Expects continued R&D expenditures as clinical and preclinical programs advance.

• Plans to utilize IPO proceeds for clinical development, regulatory approval, commercialization, and pipeline expansion through 2029.

• Focused on maximizing senaparib's global value, expanding the pipeline, and leveraging partnerships.

• EMA approval for senaparib in Europe anticipated in the second half of 2026.